10261-82-2Relevant articles and documents
Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration
Bowers, Simeon,Truong, Anh P.,Jeffrey Neitz,Hom, Roy K.,Sealy, Jennifer M.,Probst, Gary D.,Quincy, David,Peterson, Brian,Chan, Wayman,Galemmo Jr., Robert A.,Konradi, Andrei W.,Sham, Hing L.,Tóth, Gergely,Pan, Hu,Lin, May,Yao, Nanhua,Artis, Dean R.,Zhang, Heather,Chen, Linda,Dryer, Mark,Samant, Bhushan,Zmolek, Wes,Wong, Karina,Lorentzen, Colin,Goldbach, Erich,Tonn, George,Quinn, Kevin P.,Sauer, John-Michael,Wright, Sarah,Powell, Kyle,Ruslim, Lany,Ren, Zhao,Bard, Frédérique,Yednock, Ted A.,Griswold-Prenner, Irene
, p. 5521 - 5527 (2011)
The SAR of a series of brain penetrant, trisubstituted thiophene based JNK inhibitors with improved pharmacokinetic properties is described. These compounds were designed based on information derived from metabolite identification studies which led to compounds such as 42 with lower clearance, greater brain exposure and longer half life compared to earlier analogs.
NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS
-
, (2020/06/01)
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF
-
Paragraph 0430; 0431; 0432, (2015/11/30)
A compound represented by Formula [1] (in the formula, Z1 represents N, CH, or the like; X1 represents NH or the like; R1 represents a heteroaryl group or the like; each of R2, R3, and R4 represents a hydrogen atom, a halogen atom, an alkoxy group, or the like; and R5 represents a heteroaryl group or the like) or salt thereof.
HETEROBICYCLIC COMPOUNDS
-
Paragraph 1019, (2013/09/12)
Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.